Evidence map›Paper›PMID 24210784›Full record

ArticleCytotherapy2014

Amniotic fluid stem cells prevent β-cell injury.

Valentina Villani, Anna Milanesi, Sargis Sedrakyan, Stefano Da Sacco, Susanne Angelow, Maria Teresa Conconi, Rosa Di Liddo, Roger De Filippo, Laura Perin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. The PI3K/AKT pathway in obesity and type 2 diabetes.International journal of biological sciences · 2018
    Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Valentina VillaniDepartment of Urology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California.
Anna MilanesiDivision of Endocrinology, VA Greater Los Angeles Healthcare System, University of California Los Angeles, Los Angeles, California.
Sargis SedrakyanDepartment of Urology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California.
Stefano Da SaccoDepartment of Urology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California.
Susanne AngelowDepartment of Urology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California.
Maria Teresa ConconiDepartment of Pharmaceutical Sciences, University of Padua, Padua, Italy.
Rosa Di LiddoDepartment of Pharmaceutical Sciences, University of Padua, Padua, Italy.
Roger De FilippoDepartment of Urology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California.
Laura PerinDepartment of Urology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California. Electronic address: lperin@chla.usc.edu.
University of Southern California · USChildren's Hospital of Los Angeles · USUniversity of Padua · ITUniversity of California, Los Angeles · US

Funding

Thyroid Hormone Receptor Isoforms in Skeletal MuscleK08DK097295 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MILANESI, ANNA · 2013 to 2016
$648k
NIDDK NIH HHS K08 DK097295
6 · The paper itself

Abstract

BACKGROUND

aimsThe contribution of amniotic fluid stem cells (AFSC) to tissue protection and regeneration in models of acute and chronic kidney injuries and lung failure has been shown in recent years. In the present study, we used a chemically induced mouse model of type 1 diabetes to determine whether AFSC could play a role in modulating β-cell injury and restoring β-cell function.

methodsStreptozotocin-induced diabetic mice were given intracardial injection of AFSC; morphological and physiological parameters and gene expression profile for the insulin pathway were evaluated after cell transplantation.

resultsAFSC injection resulted in protection from β-cell damage and increased β-cell regeneration in a subset of mice as indicated by glucose and insulin levels, increased islet mass and preservation of islet structure. Moreover, β-cell preservation/regeneration correlated with activation of the insulin receptor/Pi3K/Akt signaling pathway and vascular endothelial growth factor-A expression involved in maintaining β-cell mass and function.

conclusionsOur results suggest a therapeutic role for AFSC in preserving and promoting endogenous β-cell functionality and proliferation. The protective role of AFSC is evident when stem cell transplantation is performed before severe hyperglycemia occurs, which suggests the importance of early intervention. The present study demonstrates the possible benefits of the application of a non-genetically engineered stem cell population derived from amniotic fluid for the treatment of type 1 diabetes mellitus and gives new insight on the mechanism by which the beneficial effect is achieved.

Indexed as

Acute Kidney InjuryAmniotic FluidAnimalsCell- and Tissue-Based TherapyDiabetes Mellitus, ExperimentalDisease Models, AnimalHumansInjectionsInsulinInsulin-Secreting CellsLungMiceRegenerationStem CellsStem Cell TransplantationInsulinamniotic fluidpancreasregenerationstem cellstype 1 diabetes mellitusβ-cell

Identifiers

PMID24210784
PMCPMC4374982
OpenAlexW2081691974

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.